The addition of tarextumab to nab-paclitaxel and gemcitabine (Nab-P+Gem) in Patients (pts) with Untreated Metastatic Pancreatic Cancer (mPC) was herein reported in the final clinical results of Phase 3 trial of Nab-P+Gem in combination with tarextumab (TRXT) (NCT01930014). Tarextumab (TRXT) is a fully human IgG2 that inhibits Notch 2 and 3. No further development of tarextumab is planned in advanced pancreas cancer.

We previously reported a Phase 3 randomized controlled trial of an anti-Notch 2/3 agent, tarextumab (TRXT), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) for pts with untreated mPC. In this trial, pts were randomized to receive Nab-P+Gem alone (P+Gem) or the addition of TRXT at 2.5 mg/kg to 15 mg/kg (Nab-P+Gem+TRXT) in a 3-week treatment cycle, TRXT at 5 mg/kg was selected as Phase 2 dose in combination with Nab-P+Gem. Medians (95% CI) of progression-free survival (PFS) and overall survival (OS) were evaluated in the ALPINE study: a Phase 1b/2 trial of nab-paclitaxel and gemcitabine (P+Gem) in pts with untreated metastatic pancreatic adenocarcinoma. nab-paclitaxel and gemcitabine (P+Gem) was evaluated in the ALPINE study: a Phase 1b/2 trial of nab-paclitaxel and gemcitabine (P+Gem) in patients with untreated metastatic pancreatic cancer, DLT assessed on Days 1, 8 and 15 of q28 days.

The addition of TRXT did not change chemotherapy dose intensity.